Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation
Kristine A. Frerichs, Christie P.M. Verkleij, María‐Victoria Mateos, et al.
Blood Advances (2023) Vol. 8, Iss. 1, pp. 194-206
Open Access | Times Cited: 33

Showing 1-25 of 33 citing articles:

Teclistamab-Induced Remission in Refractory Systemic Lupus Erythematosus
Tobias Alexander, Jan Krönke, Qingyu Cheng, et al.
New England Journal of Medicine (2024) Vol. 391, Iss. 9, pp. 864-866
Closed Access | Times Cited: 16
Bispecific antibodies in the treatment of multiple myeloma
Anup J. Devasia, Ajai Chari, Guido Lancman
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 12
Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study
Carlyn Tan, Sireesha Asoori, Chiung‐Yu Huang, et al.
Blood Cancer Journal (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 1
IgG replacement in multiple myeloma
Alex Wonnaparhown, Talal Hilal, Jacqueline D. Squire, et al.
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 7
Bispecific Antibody Use in Patients With Lymphoma and Multiple Myeloma
Adam Braun, Sushanth Gouni, Astrid E. Pulles, et al.
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 6
Bispecific antibodies for the treatment of relapsed/refractory multiple myeloma: updates and future perspectives
Ricardo Parrondo, Sikander Ailawadhi, Claudio Cerchione
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 5
Proposal for harmonizing the reporting of infections during treatment with bispecific antibodies in multiple myeloma
Heinz Ludwig, Nikhil Munshi, Evangelos Terpos, et al.
Blood Advances (2024) Vol. 8, Iss. 18, pp. 4979-4982
Open Access | Times Cited: 4
Novel Treatment Options for Multiple Myeloma
Andrew J. Portuguese, Rahul Banerjee, Gui Zhen Chen, et al.
JCO Oncology Practice (2025)
Closed Access
Incidence and Characteristics of Infectious Complications in Multiple Myeloma Patients Treated With Bispecific Antibodies
Taekeun Park, S. Jang, Youngil Koh, et al.
Journal of Korean Medical Science (2025) Vol. 40
Open Access
Expert Perspectives on Current Challenges and Emerging Approaches for Multiple Myeloma: Narrative Review of an Inaugural Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma
Ajai Chari, Susan Bal, Sikander Ailawadhi, et al.
Clinical Lymphoma Myeloma & Leukemia (2025)
Closed Access
CAR T-cell therapy in autoimmune diseases: where are we and where are we going?
Marc Scherlinger, Gaëtane Nocturne, Marko Radic, et al.
The Lancet Rheumatology (2025)
Closed Access
Real-world treatment patterns for teclistamab and talquetamab in multiple myeloma (MM): experience from 609 patients
F. Chunara, Chris Lugo, Kristen Osinski, et al.
Blood Cancer Journal (2025) Vol. 15, Iss. 1
Open Access
Perspectives on Outpatient Delivery of Bispecific T-Cell Engager Therapies for Multiple Myeloma
Andrée-Anne Pelland, Marc‐Emmanuel Dumas, Émilie Lemieux‐Blanchard, et al.
Current Oncology (2025) Vol. 32, Iss. 4, pp. 238-238
Open Access
Case Report: Teclistamab in the treatment of idiopathic immune thrombocytopenia in patients with multiple myeloma
Asis Shrestha, Anup Kumar Trikannad Ashwini Kumar, Soumya Pandey, et al.
Frontiers in Hematology (2025) Vol. 4
Open Access
T-Cell Redirecting Therapies in Multiple Myeloma: Pathogenesis and Management of Toxicities Beyond CRS and ICANS
Katia Mancuso, Marco Talarico, Enrica Manzato, et al.
Cancers (2025) Vol. 17, Iss. 9, pp. 1514-1514
Open Access
Monitoring M-Protein, Therapeutic Antibodies, and Polyclonal Antibodies in a Multiparametric Mass Spectrometry Assay Provides Insight into Therapy Response Kinetics in Patients with Multiple Myeloma
Charissa Wijnands, Peter Karel, Jolein Gloerich, et al.
Pharmaceutics (2025) Vol. 17, Iss. 1, pp. 135-135
Open Access
Approaches To Managing Relapsed Myeloma: Switching Drug Class or Retreatment With Same Drug Class?
Rohit Vijjhalwar, Aarthi Kannan, Cynthia Fuentes-Lacouture, et al.
Indian Journal of Hematology and Blood Transfusion (2025)
Open Access
Prolonged COVID-19 Pneumonia in Patients with Hematologic Malignancies: Clinical Significance and Serial CT Findings
Dae Hee Han, Raeseok Lee, Gi June Min, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 8, pp. 2701-2701
Open Access
Improving outcomes with anti-BCMA bispecific antibodies with attention to infection
Andrew J. Yee
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 3
Progressive Multifocal Leukoencephalopathy Unmasked by Teclistamab in a Refractory Multiple Myeloma Patient
Panos Arvanitis, Dimitrios Farmakiotis, Ari Pelcovits
Current Oncology (2024) Vol. 31, Iss. 5, pp. 2670-2678
Open Access | Times Cited: 2
Anti-BCMA CAR-T cell-based therapies and bispecific antibodies in the immunotherapy era: are we ready for this?
Massimo Martino, Barbara Gamberi, Elisabetta Antonioli, et al.
Expert Review of Hematology (2024) Vol. 17, Iss. 7, pp. 375-390
Open Access | Times Cited: 2
Defining infection risk of bispecific antibodies for myeloma
Sarah P. Hammond
Blood Advances (2024) Vol. 8, Iss. 18, pp. 4977-4978
Open Access | Times Cited: 1
Recommendations for the effective use of T-cell–redirecting therapies: a Canadian consensus statement
Guido Lancman, Kevin Song, Darrell White, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 1
Endothelial injury and dysfunction with emerging immunotherapies in multiple myeloma, the impact of COVID-19, and endothelial protection with a focus on the evolving role of defibrotide
Clifton C. Mo, Edward Richardson, Eleonora Calabretta, et al.
Blood Reviews (2024) Vol. 66, pp. 101218-101218
Open Access | Times Cited: 1
T-cell redirecting bispecific antibody treatment in multiple myeloma: current knowledge and future strategies for sustained T-cell engagement
Marise R. Heerma van Voss, Remco J. Molenaar, Charlotte L.B.M. Korst, et al.
Expert Opinion on Biological Therapy (2024) Vol. 24, Iss. 9, pp. 889-901
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top